Background: Appropriate vaccination strategies have been key to controlling the outbreak of mpox outside endemic areas in 2022, yet few studies have provided information on mpox vaccine effectiveness (VE). Aim: To assess VE after one dose of a third-generation smallpox vaccine against mpox when given as post-exposure prophylaxis (PEP) within 14 days. Methods: A survival analysis in a prospective cohort of close contacts of laboratory-confirmed mpox cases was conducted from the beginning of the outbreak in the region of Madrid in May 2022. The study included contacts of cases in this region diagnosed between 17 May and 15 August 2022. Follow up was up to 49 days. A multivariate proportional hazard model was used to evaluate VE in the presence of confounding and interaction. Results: Information was obtained from 484 close contacts, of which 230 were vaccinated within 14 days of exposure. Of the close contacts, 57 became ill during follow-up, eight vaccinated and 49 unvaccinated. The adjusted effectiveness of the vaccine was 88.8% (95% CI: 76.0–94.7). Among sexual contacts, VE was 93.6% (95% CI: 72.1–98.5) for non-cohabitants and 88.6% (95% CI: 66.1–96.2) for cohabitants. Conclusion: Post-exposure prophylaxis of close contacts of mpox cases is an effective measure that can contribute to reducing the number of cases and eventually the symptoms of breakthrough infections. The continued use of PEP together with pre-exposure prophylaxis by vaccination and other population-targeted prevention measures are key factors in controlling an mpox outbreak.
Background: Since May 2022, an mpox outbreak affecting primarily men who have sex with men (MSM) has occurred in numerous non-endemic countries worldwide. As MSM frequently reported multiple sexual encounters in this outbreak, reliably determining the time of infection is difficult; consequently, estimation of the incubation period is challenging. Aim: We aimed to provide valid and precise estimates of the incubation period distribution of mpox by using cases associated with early outbreak settings where infection likely occurred. Methods: Colleagues in European countries were invited to provide information on exposure intervals and date of symptom onset for mpox cases who attended a fetish festival in Antwerp, Belgium, a gay pride festival in Gran Canaria, Spain or a particular club in Berlin, Germany, where early mpox outbreaks occurred. Cases of these outbreaks were pooled; doubly censored models using the log-normal, Weibull and Gamma distributions were fitted to estimate the incubation period distribution. Results: We included data on 122 laboratory-confirmed cases from 10 European countries. Depending on the distribution used, the median incubation period ranged between 8 and 9 days, with 5th and 95th percentiles ranging from 2 to 3 and from 20 to 23 days, respectively. The shortest interval that included 50% of incubation periods spanned 8 days (4–11 days). Conclusion: Current public health management of close contacts should consider that in approximately 5% of cases, the incubation period exceeds the commonly used monitoring period of 21 days.
Introduction: An appropriate vaccination approach is critical to control the current outbreak of mpox but there is little research providing information on its effectiveness, particularly under circumstances of limited vaccine availability. Methods: Pre-exposure vaccination campaign in the Madrid region, with the modified vaccinia Ankara-Bavarian Nordic was indicated in the risk groups from 18 July 2022. To evaluate the vaccine effectiveness (VE) of a dose of third-generation smallpox vaccine against mpox in the context of pre-exposure prophylaxis, a population-based indirect cohort study (Broome method) also known as test-negative design (TND) was conducted in the Madrid region (6 751 251 inhabitants). Logistic regression was used to obtain the adjusted VE in the TND with its time–response relationship and for the sensitivity analysis the conditional logistic regression for matched case–control groups. Results: By epidemiological surveillance, 1690 suspected episodes of mpox were detected of which 799 were cases and 891 controls. The overall adjusted effectiveness of the pre-exposure vaccination against mpox considering an induction period of 14 days, was 86.4% (95% CI 62.2% to 95.1%). VE increases, with a statistically significant time–response effect, being greater than 77.4% with a 95% confidence level from week 7. The VE at eighth week of vaccination was 99% (95% CI 81.7% to 99.9%). Conclusions: The effectiveness of single-dose pre-exposure vaccination against mpox seems very high. Therefore, it appears as a reliable measure to minimise the spread of mpox. The progressive increase in the effectiveness could justify the delay in the administration of the second dose in situations of shortage of vaccines or prioritisation in the vaccination of the maximum number of subjects at risk. Further studies evaluating the long-term effectiveness of the full vaccination would be appropriate.
Eurosurveillance.org is the online home of Eurosurveillance, Europe's journal on infectious disease surveillance, epidemiology, prevention and control.
13 August 2026 in European Journal of Clinical Microbiology & Infectious Diseases